Race CEO Dr Daniel Tillett spoke with Johnathan Jackson at Proactive about the completion of GLP studies for RC220 bisantrene. Dr Tillett noted that the studies demonstrated excellent safety profile for RC220 bisantrene. It gives the new formulation of bisantrene…
The Australian reports that Race Oncology has appointed George Clinical as the Contract Research Organisation to support the Phase 1a/1b trial for RC220 bisantrene in solid tumour patients. Read the full article here.
The Motley Fool reports on the exciting news that Race has received today. The US Food and Drug Administration (FDA) has extended Rare Paediatric Disease Designation to RC220 bisantrene for the treatment of paediatric acute myeloid leukemia. Read the full…
The Australian reports that The US Food and Drug Authority (FDA) has extended Rare Paediatric Disease Designation (RPDD) to Race’s oncology drug RC220 bisantrene for paediatric acute myeloid leukemia (AML). The RPDD in paediatric AML may qualify Race to be…
Proactive reports that Race has hit a new 12-month high on fielding some strong preclinical findings on the efficacy of lead asset bisantrene in treating multiple myeloma. Race CEO Dr Daniel Tillett commented: “The potential for using bisantrene to not only…
The United States Food and Drug Administration (FDA) has extended Orphan Drug Designation (ODD) to our proprietary formulation of bisantrene, RC220, for acute myeloid leukemia. Race CEO Dr Daniel Tillett spoke with Proactive about this significant announcement and the commercial…
